| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Bosentan | 147536-97-8 | sc-210957 | 10 mg | $195.00 | 3 | |
This dual endothelin receptor antagonist (ERA) is investigated for its use in regard to pulmonary arterial hypertension. | ||||||
Ambrisentan | 177036-94-1 | sc-207276 | 5 mg | $348.00 | ||
Another selective endothelin receptor antagonist used for pulmonary arterial hypertension. | ||||||
Sitaxsentan Sodium | 210421-74-2 | sc-215857 | 10 mg | $640.00 | ||
A selective endothelin receptor antagonist that was previously approved for pulmonary arterial hypertension but has been withdrawn from the market. | ||||||
Atrasentan Hydrochloride | 195733-43-8 | sc-503157 | 50 mg | $490.00 | ||
It is an endothelin receptor antagonist being studied for its potential in diabetic kidney disease and prostate cancer. | ||||||
BQ-123, Sodium Salt | 136655-57-7 | sc-391073 sc-391073A | 1 mg 5 mg | $123.00 $418.00 | 1 | |
A selective endothelin receptor antagonist primarily targeting the endothelin A receptor. | ||||||
CI 1020 | 162256-50-0 | sc-204687 sc-204687A | 10 mg 50 mg | $175.00 $793.00 | ||
A non-peptide endothelin receptor antagonist with a preference for the endothelin A receptor. | ||||||
Zibotentan | 186497-07-4 | sc-364662 sc-364662A | 5 mg 10 mg | $340.00 $640.00 | ||
It is an endothelin receptor antagonist that has been studied for prostate cancer. | ||||||
Lixivaptan | 168079-32-1 | sc-489378 | 5 mg | $84.00 | ||
While not a direct ET-1 inhibitor, lixivaptan is a vasopressin V2 receptor antagonist that indirectly affects the ET-1 pathway by modulating fluid balance. | ||||||